All the below links and tweets are in English.
France Vol.15 (pharmaceutical corporations: Sanofi)
France Vol.16 (pharmaceutical corporations: Ipsen, Servier)
France Vol.17 (pharmaceutical corporations) Pierre Fabre, LFB Biotechnologies
ツイッター検索で 上記5製薬会社各社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
1/ We were honored to host dinner this week to celebrate the closing of the @TakedaPharma acquisition of Shire and to welcome new USAIC Board Members: John Reed of @Sanofi Phillip Larsen of @Bayer and John Orloff of @AlexionPharma pic.twitter.com/W2TOzaJW6i
— USAIC (@USAIC) January 30, 2020
Through research we commissioned with @EIUPerspectives in the US, Japan and Europe, gaps have been uncovered in #cancer care for the aging, and the impact those gaps can have on healthcare systems. Find out more. #WhenCancerGrowsOld
— Sanofi (@sanofi) June 18, 2020
Through research with @TheEconomist in the U.S., Japan and Europe, we’ve uncovered gaps in #cancer care for the aging, and the impact those challenges can have on healthcare systems. Find out more about what we learned. #WhenCancerGrowsOld
— Sanofi (@sanofi) February 10, 2020
#DRG epidemiology report estimates more than 8.5 million diagnosed events of #RSV across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #respiratorysyncytialvirus @sanofi https://t.co/qmI5DN8A8D
— DRG Epidemiology (@DRG_Epi) December 19, 2019
#DRG epidemiology report estimates more than 28 million #influenza events across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #flu #ESCCongress #OurHeartIsInIt @sanofi https://t.co/b9ro3FzMDn
— DRG Epidemiology (@DRG_Epi) September 5, 2019
Currently, more than 190 million people suffer from #allergicrhinitis across the United States, Western Europe and Japan. Follow us for more updates on #DRG epidemiology data and forecast trends @DRGinsights @sanofi #WorldAllergyWeek https://t.co/UwFVqRvZUF
— DRG Epidemiology (@DRG_Epi) April 11, 2019
#DRG epidemiology report estimates nearly 30 million #influenza #flu events across the United States, Western Europe and Japan. @DRGinsights @sanofi https://t.co/aMX8ZwAEY0
— DRG Epidemiology (@DRG_Epi) August 22, 2018
J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports | @AstraZeneca @JNJ @gatesfoundation @melindagates @BillGates @UniofOxford @BARDA @Sanofi @Moderna @Pfizer @BioNTech @Curevac @GSK #covid19 #vaccine #Biotech https://t.co/cRcjPrjCy9
— Aspen Biosciences (@aspenbio) July 19, 2020
.@sanofi, the company that produces #Lantus, had already filed 74 patents for the drug in the US by 2018 – this is 1.5 times more than those in Europe, and almost triple than in Japan. pic.twitter.com/HBjUqpT2NU
— I-MAK (@IMAKglobal) November 8, 2019
How about a deal with @SangamoTx to better exploit protein homeostasis? Hematology is unpartnered @ScienceAtBMS @bmsnews @JoeSzustakowski.
Partners include @sanofi @NovartisScience @pfizer #takeda @GileadSciences @KitePharma @biogen$SGMO $BMY $PFE $NVS $SNY $GILD $BIIB https://t.co/tJzQPwFTgB— biotech 2050 (@Biotech2050) July 30, 2020
Also underlines the integrated approach championed by the @WHO i.e vaccine(s) alone are not the solution we have to pull together #diagnostics #communityengagement #vectorcontrol & is exactly why we are advocating for a @WorldDengueDay to be officially recognised @sanofi @Takeda https://t.co/NtOGRRTIar
— ISNTD (@ISNTD_Press) July 14, 2020
The key players in Non-Small Cell Lung Cancer #market include @Novartis, @Merck, @LillyPad, Hoffmann-La-@Roche, @Xcovery, @beyondspring26, @OSEIMMUNO, @sanofi, @Takeda, @abbvie and others.
For more detailed information visit: https://t.co/RWk90xqKhl#LungCancer #Cancer
— DelveInsight (@delve_insight) May 12, 2020
#Takeda’s #dengue shot, rival to #Sanofi's #Dengvaxia, hits the mark in massive phase 3 study https://t.co/GlYlVhHlSZ @FiercePharma @TakedaPharma @sanofi #vaccine #denguevirus
— Plexus Ventures (@PlexusVentures) January 30, 2019
Top pharma execs discuss and share #bestpractices of what they're doing to meet the challenges of COVID-19 @LillyPad @JNJNews @Roche @Sanofi @Takeda @IFPMA https://t.co/HngTgXpJtH
— Ogilvy Cambridge (@OgilvyCambridge) March 20, 2020
Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx
— Open Targets (@targetvalidate) June 21, 2019
Global Candida Infections Drugs Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Abbott, Pfizer Inc., Novartis AG, Merck & Co., Inc, Sanofi, Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plchttps://t.co/d7povpUALz#new
— Pharma News (@pharminews) September 8, 2020
Global Prostate Cancer Therapeutics Market Likely to Experience a Tremendous Growth in Near Future|| Johnson & Johnson Services, Inc., Astellas Pharma US, Inc., Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd., Bayer AGhttps://t.co/A1PMeJ5FeY#news #pharma #pharmiweb
— Pharma News (@pharminews) August 5, 2020
Pharmaceutical Technology – #October’s top #news #stories https://t.co/xHDYOFwX6W #UCB #RA | #Novartis #Microsoft | #Sobi #Dova | #Sanofi US #manufacturing | #Alexion #Achillion | #Bavarian Nordic #GSK | #Daiichi #Astellas | #Ipsen #Blueprint | …
— GESDAT GmbH (@GESDAT) November 5, 2019
FiercePharmaAsia—Sanofi's Japan cuts; Big Pharma CEOs' Chinese names; Astellas' ESMO win: https://t.co/RbSO8pbM2i #pharma #regulatory
— Pharma Regulatory (@EURegulatory) October 4, 2019
Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7
— ABNewswire (@ABNewswire) September 13, 2019
Global Urinary Drugs Market 2019 – Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Pfizer Inc., Bayer AG – Honest News 24
https://t.co/kHgcMcepxG— News SummedUp Kenya (@summedupkenya) July 17, 2019
It's Friday afternoon & time for #WeeklyRoundup Read the full article here: https://t.co/cJ5QMOVX5Z
Companies included: @Amgen @astellas @GSK@MSDInvents @Novartis @Pfizer_Ireland @sanofi @VertexPharma#MarketWatch #ThePMI19 pic.twitter.com/wB4do7MdZK— The PMI (Pharmaceutical Managers' Institute) (@PharmaMgrsInst) January 25, 2019
Big Pharma – Novartis, Pfizer, Sanofi, Otsuka – has decided to partner, rather than rival, with Alphabet's Verily to accelerate clinical trials. Here's a story I wrote about how Alphabet and Apple's clinical trial strategies differ https://t.co/fpW0j2H6hw https://t.co/6xM4gemxEW
— Hannah Kuchler (@hannahkuchler) May 21, 2019
The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf
— FierceBiotech (@FierceBiotech) May 21, 2019
Novartis, Sanofi, Otsuka, and Pfizer will work with Alphabet’s #Verily on its #ProjectBaseline clinical research project https://t.co/kLtditGb31
— pharmaphorum (@pharmaphorum) May 22, 2019
As mentioned earlier, Verily, Google's health care division, is also collaborating with Sanofi, Novartis, Otsuka and Pfizer to help them identify suitable patients for clinical drug trials. #digitalmarketing #optimization #growthhacking https://t.co/X1jXvUzYZu
— MRVSKY (@mrvskypro) December 1, 2019
Amgen, Sanofi back a round for real-world evidence platform tech; Daiichi Sankyo’s pexidartinib secures speedy FDA review https://t.co/ic5dkzRo5Y
— Endpoints News (@endpts) February 5, 2019
Sanofi, Eisai join Lilly's SCOTUS bid to save Cialis from 'overly broad' patent claims https://t.co/2rBBlgNDID
— FiercePharma (@FiercePharma) July 9, 2019
https://t.co/sxLYhMpxvg – #Clinical #Catch–#up for June 10-14
https://t.co/XYnsCW41Fh #Sanofi #Lilly #ProventionBio #Eisai #Novartis #Genentech #Savara #BluebirdBio #Janssen #Hutchison #China #Meditech— GESDAT GmbH (@GESDAT) June 18, 2019
Global Prostate Cancer Therapeutics Market 2026 – Sanofi, Takeda, Johnson & Johnson, Teva Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Ipsenhttps://t.co/MqR8Y7rxmL#news #pharma #pharmiweb
— Pharma News (@pharminews) June 23, 2020
Medicine Fact's:
FEBUXOSTATFebuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe pic.twitter.com/iL1QiQyFES
— PharmahubNG (@pharmahub_NG) April 23, 2020
https://twitter.com/debasisdas/status/1191697468997505025
Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview & Product Profiles 2019 – https://t.co/8vPVgQlQhj https://t.co/QBZCpYtRTH
— Pharmacutical Daily (@PharmacDaily) June 26, 2019
#Ipsen joins @Arixbioscience’s growing pool of pharma partners #biotech #pharma #biopharma #biotechnology #VC #venturecapital #partnerships #EuroBiotech #France #UK #Fosun #Takeda #UCB $IPN $ARIX https://t.co/548ySCuIyC via @FierceBiotech
— Kara Jill Stancell (@kjilly) February 21, 2018
#Japanese #cancer Japanese regulators grant additional approval for the sale of Ipsen's rare cancer drug in Japan https://t.co/pmEsO6Mcov pic.twitter.com/MDv7v96yVV
— PharmaSources.com (@Pharmachina365) July 5, 2017
#efpbarca #medaffairs Ipsen, Eisai, and Astellas on why communicating data to external stakeholders is essential. Find out more here: https://t.co/6p0SXN2R3C pic.twitter.com/o4UdkJxsR8
— The Pharmaceutical Marketing Group (@PharmaMKTnet) October 24, 2018
https://twitter.com/Servier/status/1275363363812450305
https://twitter.com/Servier/status/1273889368801935360
https://twitter.com/Servier/status/1270038222144495616
https://twitter.com/ServierCDMO/status/987605428904366080
Onivyde Now Available in Japan: Servier/Yakult Nihon Servier and Yakult Honsha rolled out its cancer agent Onivyde (liposomal irinotecan) in Japan … https://t.co/h0pZ4komgH
— MEDWAVE (@medinfoa2z) June 2, 2020
Yakult to Promote Servier’s Anticancer Agent Liposomal Irinotecan in Japan Yakult Honsha and Nihon Servier, the Japan unit of the France-based Servier Group, have entered into… https://t.co/IuNVzWp4wK
— MEDWAVE (@medinfoa2z) October 9, 2019
https://twitter.com/conkers3/status/986959011038879744
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one https://t.co/ie1viNsPi6 pic.twitter.com/VVjxrD1Jz3
— Endpoints News (@endpts) April 16, 2018
Shire's oncology exit weighs on potential Takeda bid: Shire plc is backing out of cancer drugs, announcing Monday the sale of its oncology business to French pharma Servier S.A.S. for $2.4 billion in cash. https://t.co/6TcuucnAtl
— cafepharma (@cafepharma) April 17, 2018
Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles https://t.co/YexpoARs1k pic.twitter.com/yASy7SXm3Z
— Reuters (@Reuters) April 16, 2018
For those interested in the life sciences sector: Shire will be selling its oncology business to French company Servier for $2.4 billion — could this move prevent Japan's Takeda from making a takeover bid for Shire? https://t.co/fQJ2NzF4lA #lifesciences pic.twitter.com/In5rrSyKRn
— Chambers Associate (@ChambersAssoc) April 16, 2018
$SHPG announced today that they are willing to sell their oncology business to France's Servier SAS for about $2.4 billion, as it continues to discuss another possible $50 billion takeover by Japan's Takeda Pharmaceutical. https://t.co/UKVAuq8fLE pic.twitter.com/FG6cAk2Gle
— Stock Analyst (@USCheapStocks) April 16, 2018
#Japan @Takeda @Reuters @London @Japan @TakedaPharmaceutical @Servier #Cancer #DYK #AllThingsCancer #CancerMoonShot #EndCancer #FindACure #CancerTodayMag #JoinTheFight #CancerResearch https://t.co/lN4EPjg7gQ
Shire sells cancer drugs to #Servier as #Takeda circles— Ken Nitz (@knitz22) April 16, 2018
Three days until our West Coast Conference in L.A.! If you haven’t registered yet, there’s still time: https://t.co/Q2741YJGmW Huge thanks to our sponsors: @genentech @hsn @pfizerinc @pgbeauty @qvc @novartis, Eisai, @LLSusa & @Servier ✨ #bethebossovercancer #CACwestcoast pic.twitter.com/bSd4KXpTUy
— Cancer and Careers (@CancerAndCareer) October 23, 2019
Pharmaceutical Formulations for Asia from Japan
Pierre Fabre, a leading French manufacturer of pharmaceutical products and dermatological cosmetics, opened its Asia Innovation Center PFDC in Japan in 2014 and began formulations activities … https://t.co/6KNKghWWMd pic.twitter.com/Syp79UHJiW— HC_Tokyo (@nadoCb) February 3, 2018
